Company intelligence / Profile preview
Lexicon Pharmaceuticals, Inc.
The Woodlands, Texas, United Stateslexpharma.com ↗
- Ownership
- Public · LXRX
- Development stage
- Other
01
Overview
Lexicon has FDA approval for Inpefa (sotagliflozin) for heart failure. The company recently announced a strategic shift to focus on R&D, cutting commercial operations while maintaining manufacturing of Inpefa. Their LX9211 for diabetic peripheral neuropathic pain is in Phase 2b with data expected in Q2 2025. They also faced a setback with Zynquista (sotagliflozin) for type 1 diabetes, receiving a deficiency notice from the FDA in 2024.
- Therapeutic areas
- CardiovascularMetabolic DisordersNephrologyEndocrinologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Viatris Inc.Bristol-Myers Squibb Company
04
Financials
- Market cap
- $716.4M
- Total revenue
- $49.8M
- Enterprise value
- $394.1M
Beyond the preview
Go deeper on Lexicon Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lexicon Pharmaceuticals, Inc..